Application to Predict Neonatal Apnea With Bradycardia
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Feb 24, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to help pre-term infants who experience breathing pauses (called apnea) and slow heart rates (called bradycardia). The goal is to find out if gentle stimulation can help prevent these episodes from happening. This is important because apnea and bradycardia can be serious for newborns, especially those born early.
To participate in this study, infants must have had documented episodes of apnea with bradycardia in the past day and should not have been on breathing support for at least two days. They should also have been born at less than 32 weeks of gestation. Parents or legal guardians will need to give their permission for their baby to join the study. It’s important to note that babies with certain serious health conditions will not be eligible. The study is not currently recruiting participants, but it aims to provide valuable insights into improving care for these vulnerable infants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented episodes of apnea with bradycardia over the previous 24 hours.
- • Off ventilatory support/NCPAP for \> 48 hours prior to study entry
- • Gestational age \< 32 0/7 weeks' gestation at birth
- • Parents/legal guardians have provided consent for enrollment
- Exclusion Criteria:
- • a major malformation or a neuromuscular condition that affects respiration or causes apnea, or terminal illness or decision to withhold or limit support.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Colm P. Travers Associate Professor of Pediatrics, M.D.
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported